ReviewBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2012
Progress in haploidentical stem cell transplantation.
Review in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03480360 (Haploidentical Allogeneic Peripheral Blood Transplantation), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Haploidentical Allogeneic Peripheral Blood Transplantation: Clinical Trial and Laboratory Correlates Examining Checkpoint Immune Regulators' Expression
Who cites it
13 citing papers in PubMed, 42 citations in OpenAlex.
- Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016Trial
- A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients.Cancer chemotherapy and pharmacology · 2013Trial
- Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2012Trial
- Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation.Blood advances · 2020Article
- A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in Central and Southern Europe.Bone marrow transplantation · 2020Article
- Is a matched unrelated donor search needed for all allogeneic transplant candidates?Blood advances · 2018Article
- Haploidentical hematopoietic stem cell transplantation in children with high-risk hematologic malignancies: outcomes with two different strategies for GvHD prevention. Ex vivo T-cell depletion and post-transplant cyclophosphamide: 10 years of experience at a single center.Bone marrow transplantation · 2016Article
- Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I.Clinical pharmacokinetics · 2016Review
- Immunity to Infections after Haploidentical Hematopoietic Stem Cell Transplantation.Mediterranean journal of hematology and infectious diseases · 2016Review
- Haploidentical Hematopoietic Stem Cell Transplantation: Expanding the Horizon for Hematologic Disorders.Advances in hematology · 2016Review
- "No donor"? Consider a haploidentical transplant.Blood reviews · 2015Review
- Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study.Bone marrow transplantation · 2014Article
- Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses.Gene therapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Haploidentical stem cell transplantation is an attractive form of transplantation because of the immediate donor availability, ease of stem cell procurement, and the possibility to further collect donor cells for cellular therapy. Historically, maintaining T cells in the graft has been associated with very high rates of graft-versus-host-disease (GVHD), whereas T cell-depleted haploidentical transplantation has been limited by a higher incidence of graft rejection and nonrelapse mortality related to infectious complications as a result of delayed immune reconstitution posttransplantation. Recent approaches have attempted to eliminate the alloreactive T cells to prevent GVHD posttransplantation. Administration of high-dose cyclophosphamide early posttransplantation in combination with tacrolimus and mycophenolate mofetil has produced engraftment and GVHD rates similar to HLA-matched sibling transplants, suggesting that the most important barriers against successful haploidentical transplantation can be overcome. Future directions should focus on optimizing conditioning regimens for different diseases and prevention of disease relapse posttransplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.